1
|
Li Y, Wang S, Li G, Gao C, Cui Z, Cong M, Hu J, Zhang M, Jin X, Sun H, Kong D. The RNA-binding protein RBMS3 inhibits the progression of colon cancer by regulating the stability of LIMS1 mRNA. Cancer Med 2024; 13:e7129. [PMID: 38618967 PMCID: PMC11017296 DOI: 10.1002/cam4.7129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Revised: 03/02/2024] [Accepted: 03/11/2024] [Indexed: 04/16/2024] Open
Abstract
BACKGROUND The RNA-binding motif single-stranded interacting protein 3 (RBMS3) is a constituent of the RNA-binding motif (RBM) protein family, which assumes a pivotal role in governing cellular biogenesis processes such as the cell cycle and apoptosis. Despite an abundance of studies elucidating RBMS3's divergent roles in the genesis and advancement of various tumors, its involvement in colon cancer remains enigmatic. METHODS The present investigation employed data analysis from TCGA and GTEx to unveil that RBMS3 expression demonstrated a diminished presence in colon cancer tissues when juxtaposed with normal colon tissues. The effect of RBMS3 and LIM zinc finger domain 1 (LIMS1) on colon cancer was substantiated via animal models and cellular experiments. The connection between RBMS3 and LIM zinc finger domain 1 (LIMS1) was verified by molecular biology methods. RESULTS The study conclusively ascertained that augmenting RBMS3 expression quells the proliferation, migration, and invasion of colon cancer cells. Furthermore, the inquiry unveiled a plausible mechanism through which RBMS3 impacts the expression of LIMS1 by modulating its mRNA stability. The investigation ascertained that RBMS3 inhibits the progression of colon cancer by regulating LIMS1. The inhibitory function of LIMS1 and RBMS3 is closely intertwined in colon cancer, with knocking down LIMS1 being able to rescue the inhibitory effect of RBMS3 overexpression on the functionality of colon cancer cell CONCLUSIONS: The discernments delineate RBMS3 as a novel suppressor of cancer via LIMS1, thereby bestowing fresh therapeutic possibilities and illuminating the intricacies of colon cancer.
Collapse
Affiliation(s)
- Yafei Li
- Department of PathologyHarbin Medical UniversityHarbinChina
| | - Shuoshuo Wang
- Department of PathologyHarbin Medical UniversityHarbinChina
| | - Guoli Li
- Department of Anus and Intestine SurgeryChifeng Municipal HospitalChifengChina
| | - Chunyang Gao
- Department of AnatomyHarbin Medical UniversityHarbinChina
| | - Zihan Cui
- Department of PathologyHarbin Medical UniversityHarbinChina
| | - Mingqi Cong
- Department of PathologyHarbin Medical UniversityHarbinChina
| | - Jie Hu
- Central Operating DepartmentThe First Affiliated Hospital of Harbin Medical UniversityHarbinChina
| | - Minghui Zhang
- Department of OncologyChifeng Municipal HospitalChifengChina
| | - Xiaoming Jin
- Department of PathologyHarbin Medical UniversityHarbinChina
| | - Haiying Sun
- Gastrointestinal Rehabilitation CenterBeijing Rehabilitation Hospital of Capital Medical UniversityBeijingChina
- Gastroenterology DepartmentFirst Hospital of DandongDandongChina
| | - Dan Kong
- Department of GynaecologyTumor Hospital of Harbin Medical UniversityHarbinChina
| |
Collapse
|
2
|
Huo X, Feng D, Zhang S, Li Z, Li X, Li C, Guo M, Wang J, Zhang Z, Lu Q, Du X, Bai Z, Chen Z. Characterization and clinical evaluation of microsatellite instability and loss of heterozygosity within tumor-related genes in colorectal cancer. BMC Med Genomics 2021; 14:235. [PMID: 34563193 PMCID: PMC8466986 DOI: 10.1186/s12920-021-01051-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2020] [Accepted: 08/05/2021] [Indexed: 11/30/2022] Open
Abstract
Background Microsatellite instability (MSI) is a biomarker for better outcomes in colorectal cancer (CRC). However, this conclusion is controversial. In addition, MSs can be a useful marker for loss of heterozygosity (LOH) of genes, but this finding has not been well studied. Here, we aimed to clarify the predictive value of MSI/LOH within tumor-related genes in CRC. Methods We detected MSI/LOH of MSs in tumor-related genes and the Bethesda (B5) panel by STR scanning and cloning/sequencing. We further analyzed the relationship between MSI/LOH status and clinical features or outcomes by Pearson’s Chi-square test, Fisher’s exact test and the Kaplan–Meier method. Results The findings indicated that the MSI rates of B5 loci were all higher than those of loci in tumor-related genes. Interestingly, MSI/LOH of 2 loci in the B5 panel and 12 loci in tumor-related genes were associated with poorer outcomes, while MSI/LOH of the B5 panel failed to predict outcomes in CRC. MSI of BAT25, MSI/LOH of BAT26 and MSI of the B5 panel showed closer relationships with mucinous carcinoma. In addition, LOH-H of the B5 panel was associated with increased lymphatic metastasis. Conclusions In summary, MSI/LOH of certain loci or the whole panel of B5 is related to clinical features, and several loci within tumor-related genes showed prognostic value in the outcomes of CRC. Supplementary Information The online version contains supplementary material available at 10.1186/s12920-021-01051-5.
Collapse
Affiliation(s)
- Xueyun Huo
- School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, 100069, China
| | - Dandan Feng
- School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, 100069, China
| | - Shuangyue Zhang
- Institute of Laboratory Animal Sciences, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical Collage, Beijing, 100021 , China
| | - Zhenkun Li
- School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, 100069, China
| | - Xiaohong Li
- School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, 100069, China
| | - Changlong Li
- School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, 100069, China
| | - Meng Guo
- School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, 100069, China
| | - Jin Wang
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research & National Clinical Research Center for Digestive Diseases, Beijing, 100050, China
| | - Zhongtao Zhang
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research & National Clinical Research Center for Digestive Diseases, Beijing, 100050, China
| | - Qingxian Lu
- Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, Louisville, KY, 40202, USA
| | - Xiaoyan Du
- School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, 100069, China
| | - Zhigang Bai
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research & National Clinical Research Center for Digestive Diseases, Beijing, 100050, China.
| | - Zhenwen Chen
- School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, 100069, China.
| |
Collapse
|
3
|
Nikou S, Arbi M, Dimitrakopoulos FID, Sirinian C, Chadla P, Pappa I, Ntaliarda G, Stathopoulos GT, Papadaki H, Zolota V, Lygerou Z, Kalofonos HP, Bravou V. Integrin-linked kinase (ILK) regulates KRAS, IPP complex and Ras suppressor-1 (RSU1) promoting lung adenocarcinoma progression and poor survival. J Mol Histol 2020; 51:385-400. [PMID: 32592097 DOI: 10.1007/s10735-020-09888-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2020] [Accepted: 06/13/2020] [Indexed: 12/11/2022]
Abstract
Integrin-linked kinase (ILK) forms a heterotrimeric protein complex with PINCH and PARVIN (IPP) in Focal Adhesions (FAs) that acts as a signaling platform between the cell and its microenvironment regulating important cancer-related functions. We aimed to elucidate the role of ILK in lung adenocarcinoma (LUADC) focusing on a possible link with KRAS oncogene. We used immunohistochemistry on human tissue samples and KRAS-driven LUADC in mice, analysis of large scale publicly available RNA sequencing data, ILK overexpression and pharmacological inhibition as well as knockdown of KRAS in lung cancer cells. ILK, PINCH1 and PARVB (IPP) proteins are overexpressed in human LUADC and KRAS-driven LUADC in mice representing poor prognostic indicators. Genes implicated in ILK signaling are significantly enriched in KRAS-driven LUADC. Silencing of KRAS, as well as, overexpression and pharmacological inhibition of ILK in lung cancer cells provide evidence of a two-way association between ILK and KRAS. Upregulation of PINCH, PARVB and Ras suppressor-1 (RSU1) expression was demonstrated in ILK overexpressing lung cancer cells in addition to a significant positive correlation between these factors in tissue samples, while KRAS silencing downregulates IPP and RSU1. Pharmacological inhibition of ILK in KRAS mutant lung cancer cells suppresses cell growth, migration, EMT and increases sensitivity to platinum-based chemotherapy. ILK promotes an aggressive lung cancer phenotype with prognostic and therapeutic value through functions that involve KRAS, IPP complex and RSU1, rendering ILK a promising biomarker and therapeutic target in lung adenocarcinoma.
Collapse
Affiliation(s)
- Sofia Nikou
- Department of Anatomy-Histology-Embryology, Medical School, University of Patras, 26500, Patras, Greece
| | - Marina Arbi
- Department of General Biology, Medical School, University of Patras, 26504, Patras, Greece
| | | | - Chaido Sirinian
- Clinical and Molecular Oncology Laboratory, Division of Oncology, Medical School, University of Patras, 26504, Rio, Greece
| | - Panagiota Chadla
- Department of Anatomy-Histology-Embryology, Medical School, University of Patras, 26500, Patras, Greece
| | - Ioanna Pappa
- Department of Anatomy-Histology-Embryology, Medical School, University of Patras, 26500, Patras, Greece
| | - Giannoula Ntaliarda
- Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, 2504, Rio, Achaia, Greece
| | - Georgios T Stathopoulos
- Laboratory for Molecular Respiratory Carcinogenesis, Department of Physiology, Faculty of Medicine, University of Patras, 2504, Rio, Achaia, Greece.,Comprehensive Pneumology Center (CPC) and Institute for Lung Biology and Disease (iLBD), University Hospital, Ludwig-Maximilians University and Helmholtz Zentrum München, Member of the German Center for Lung Research (DZL), Munich, Bavaria, Germany
| | - Helen Papadaki
- Department of Anatomy-Histology-Embryology, Medical School, University of Patras, 26500, Patras, Greece
| | - Vasiliki Zolota
- Department of Pathology, University Hospital of Patras, 26504, Patras, Greece
| | - Zoi Lygerou
- Department of General Biology, Medical School, University of Patras, 26504, Patras, Greece
| | - Haralabos P Kalofonos
- Clinical and Molecular Oncology Laboratory, Division of Oncology, Medical School, University of Patras, 26504, Rio, Greece.,Division of Oncology, Department of Internal Medicine, University Hospital of Patras, 26504, Rio, Greece
| | - Vasiliki Bravou
- Department of Anatomy-Histology-Embryology, Medical School, University of Patras, 26500, Patras, Greece.
| |
Collapse
|
4
|
PINCH-1 interacts with myoferlin to promote breast cancer progression and metastasis. Oncogene 2019; 39:2069-2087. [DOI: 10.1038/s41388-019-1135-5] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2019] [Revised: 11/20/2019] [Accepted: 11/25/2019] [Indexed: 12/19/2022]
|
5
|
Li W, Ma L, Tian C. Overexpression of particularly interesting new cys-his rich protein (PINCH) is a risk factor for growth of unruptured intracranial aneurysms. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2018; 11:2636-2641. [PMID: 31938378 PMCID: PMC6958234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Accepted: 02/24/2018] [Indexed: 06/10/2023]
Abstract
Particularly interesting new cys-his rich protein (PINCH), as an adaptor protein, regulates matrix deposition, cell proliferation, invasion, and metastasis. PINCH plays an important role for tumorigenesis and progression. However, the contributions of PINCH to intracranial aneurysms (IA) remain largely unknown. In our study, we demonstrated that PINCH expression was significantly increased in IA samples compared with healthy controls. The size of IA had a remarkable correlation with PINCH expression. However, PINCH expression had no obvious difference among different Hunt-Hess grades. In addition, the expressions of MMP-2 and MMP-9 were significantly increased in IA tissues compared with healthy controls; moreover, PINCH expression in IA tissues was significantly correlated with MMP-2 and MMP-9 expression. In conclusion, these results suggest that PINCH might play a role similar to MMP-2 and MMP-9 in the pathogenesis of IA. PINCH might be a risk factor for growth of unruptured IA, and this might be a target for diagnosis and therapy of IA.
Collapse
Affiliation(s)
- Wei Li
- Department of Ultrasonography, Tianjin Huanhu HospitalTianjin 300350, China
| | - Lin Ma
- Department of Neurosurgery, Tianjin Huanhu HospitalTianjin 300350, China
| | - Chao Tian
- Department of Medical Imaging, Tianjin Huanhu HospitalTianjin 300350, China
| |
Collapse
|
6
|
Wang CJ, Zhou JW, Cheng QM, Zhou Y, Zhang H, Sun XF. FBI-1 mRNA in normal mucosa is an independent prognostic factor in colorectal cancer patients. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY 2018; 11:642-649. [PMID: 31938150 PMCID: PMC6958028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 12/08/2017] [Accepted: 12/27/2017] [Indexed: 06/10/2023]
Abstract
Although several studies provide evidence that FBI-1 is an important gene regulator in colorectal cancer (CRC), it is noteworthy that, to our knowledge, no analysis of the correlation between FBI-1 expression and prognosis in CRC has been reported. Using real-time RT-PCR, we detected FBI-1 mRNA in 161 CRC patients (primary tumor, along with the corresponding normal mucosa), 36 liver metastases, and analyzed the relationship of its expression with clinicopathological features. Colon cancer cell lines were used to study FBI-1 function. Our study found that FBI-1 was significant up-regulated in tumor tissue (2.621 ± 0.157) compared with the corresponding normal mucosa (1.620 ± 0.165, P < 0.0001). FBI-1 in normal mucosa was a prognostic factor (P = 0.039, RR 0.431, 95% CI 0.194-0.958), independent of gender, age, stage, and differentiation. High levels of FBI-1 mRNA were related with good survival. Patients with complications had a higher primary tumor FBI-1 expression than those without complications (3.400 ± 0.332 vs. 2.516 ± 0.241, P = 0.032). Suppression of FBI-1 in colon cancer cell lines could repress proliferation of cancer cells. In conclusion, FBI-1 mRNA is overexpressed in CRC, and takes part in the development of CRC. FBI-1 mRNA in normal mucosa is an independent prognostic factor. Our findings give further support to the concept of "field cancerization", and hint that when we study a biomarker, we should not only focus on the tumor tissue but also the corresponding normal mucosa.
Collapse
Affiliation(s)
- Chao-Jie Wang
- Department of Oncology, Henan Provincial People’s Hospital & People’s Hospital of Henan UniversityZhengzhou, China
- Department of Oncology and Department of Clinical and Experimental Medicine, Linköping UniversityLinköping, Sweden
| | - Jian-Wei Zhou
- Department of Oncology, Henan Provincial People’s Hospital & People’s Hospital of Henan UniversityZhengzhou, China
| | - Qiao-Mei Cheng
- Department of Oncology, Henan Provincial People’s Hospital & People’s Hospital of Henan UniversityZhengzhou, China
| | - Yun Zhou
- Department of Oncology, Henan Provincial People’s Hospital & People’s Hospital of Henan UniversityZhengzhou, China
| | - Hong Zhang
- Department of Medical Sciences, Örebro UniversityÖrebro, Sweden
| | - Xiao-Feng Sun
- Department of Oncology and Department of Clinical and Experimental Medicine, Linköping UniversityLinköping, Sweden
| |
Collapse
|
7
|
Wang MJ, Ping J, Li Y, Holmqvist A, Adell G, Arbman G, Zhang H, Zhou ZG, Sun XF. Prognostic Significance and Molecular Features of Colorectal Mucinous Adenocarcinomas: A Strobe-Compliant Study. Medicine (Baltimore) 2015; 94:e2350. [PMID: 26705231 PMCID: PMC4697997 DOI: 10.1097/md.0000000000002350] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2015] [Revised: 12/01/2015] [Accepted: 12/02/2015] [Indexed: 02/05/2023] Open
Abstract
Mucinous adenocarcinoma (MC) is a special histology subtype of colorectal adenocarcinoma. The survival of MC is controversial and the prognostic biomarkers of MC remain unclear. To analyze prognostic significance and molecular features of colorectal MC. This study included 755,682 and 1001 colorectal cancer (CRC) patients from Surveillance, Epidemiology, and End Results program (SEER, 1973-2011), and Linköping Cancer (LC, 1972-2009) databases. We investigated independently the clinicopathological characteristics, survival, and variety of molecular features from these 2 databases. MC was found in 9.3% and 9.8% patients in SEER and LC, respectively. MC was more frequently localized in the right colon compared with nonmucinous adenocarcinoma (NMC) in both SEER (57.7% vs 37.2%, P < 0.001) and LC (46.9% vs 27.7%, P < 0.001). Colorectal MC patients had significantly worse cancer-specific survival (CSS) than NMC patients (SEER, P < 0.001; LC, P = 0.026), prominently in stage III (SEER, P < 0.001; LC, P = 0.023). The multivariate survival analysis showed that MC was independently related to poor prognosis in rectal cancer patients (SEER, hazard ratios [HR], 1.076; 95% confidence intervals [CI], 1.057-1.096; P < 0.001). In LC, the integrated analysis of genetic and epigenetic features showed that that strong expression of PINCH (HR, 3.954; 95% CI, 1.493-10.47; P = 0.013) and weak expression of RAD50 (HR 0.348, 95% CI, 0.106-1.192; P = 0.026) were significantly associated with poor CSS of colorectal MC patients. In conclusion, the colorectal MC patients had significantly worse CSS than NMC patients, prominently in stage III. MC was an independent prognostic factor associated with worse survival in rectal cancer patients. The PINCH and RAD50 were prognostic biomarkers for colorectal MC patients.
Collapse
Affiliation(s)
- Mo-Jin Wang
- From the Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China (M-JW, Z-GZ, X-FS); Department of Oncology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden (M-JW, JP, AH, GA, X-FS); Department of Paediatric Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China (YL); Department of Surgery, and Department of Clinical and Experimental Medicine, Linköping University, Norrköping (GA); and School of Medicine, Örebro University, Örebro, Sweden (HZ)
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Wang MJ, Ping J, Li Y, Adell G, Arbman G, Nodin B, Meng WJ, Zhang H, Yu YY, Wang C, Yang L, Zhou ZG, Sun XF. The prognostic factors and multiple biomarkers in young patients with colorectal cancer. Sci Rep 2015; 5:10645. [PMID: 26013439 PMCID: PMC4445043 DOI: 10.1038/srep10645] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2015] [Accepted: 04/24/2015] [Indexed: 02/05/2023] Open
Abstract
The incidence of colorectal cancer (CRC) in young patients (≤50 years of age) appears to be increasing. However, their clinicopathological characteristics and survival are controversial. Likewise, the biomarkers are unclear. We used the West China (2008-2013, China), Surveillance, Epidemiology, and End Results program (1973-2011, United States) and Linköping Cancer (1972-2009, Sweden) databases to analyse clinicopathological characteristics, survival and multiple biomarkers of young CRC patients. A total of 509,934 CRC patients were included from the three databases. The young CRC patients tended to have more distal location tumours, fewer tumour numbers, later stage, more mucinous carcinoma and poorer differentiation. The cancer-specific survival (CSS) of young patients was significantly better. The PRL (HR = 12.341, 95% CI = 1.615-94.276, P = 0.010), RBM3 (HR = 0.093, 95% CI = 0.012-0.712, P = 0.018), Wrap53 (HR = 1.952, 95% CI = 0.452-6.342, P = 0.031), p53 (HR = 5.549, 95% CI = 1.176-26.178, P = 0.045) and DNA status (HR = 17.602, 95% CI = 2.551-121.448, P = 0.001) were associated with CSS of the young patients. In conclusion, this study suggests that young CRC patients present advanced tumours and more malignant pathological features, while they have a better prognosis. The PRL, RBM3, Wrap53, p53 and DNA status are potential prognostic biomarkers for the young CRC patients.
Collapse
Affiliation(s)
- Mo-Jin Wang
- 1] Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China [2] Department of Oncology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, SE 58183, Sweden
| | - Jie Ping
- Department of Oncology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, SE 58183, Sweden
| | - Yuan Li
- Department of Paediatric Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
| | - Gunnar Adell
- Department of Oncology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, SE 58183, Sweden
| | - Gunnar Arbman
- Department of Surgery, and Department of Clinical and Experimental Medicine, Linköping University, Norrköping, SE 60174, Sweden
| | - Bjorn Nodin
- Department of pathology, Lund University, Lund, SE 22100, Sweden
| | - Wen-Jian Meng
- 1] Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China [2] Department of Oncology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, SE 58183, Sweden
| | - Hong Zhang
- School of Medicine, Örebro University, Örebro, SE 70182, Sweden
| | - Yong-Yang Yu
- Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
| | - Cun Wang
- Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
| | - Lie Yang
- Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
| | - Zong-Guang Zhou
- Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
| | - Xiao-Feng Sun
- 1] Department of Gastrointestinal Surgery, Institute of Digestive Surgery and State key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China [2] Department of Oncology, and Department of Clinical and Experimental Medicine, Linköping University, Linköping, SE 58183, Sweden
| |
Collapse
|
9
|
Park CH, Rha SY, Ahn JB, Shin SJ, Kwon WS, Kim TS, An S, Kim NK, Yang WI, Chung HC. PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity. Int J Cancer 2014; 136:2273-83. [PMID: 25346044 DOI: 10.1002/ijc.29273] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2014] [Accepted: 09/30/2014] [Indexed: 01/15/2023]
Abstract
In recent years, characterization of cancer and its environment has become necessary. However, studies of the cancer microenvironment remain insufficient. Copy number variations (CNVs) occur in 40% of cancer-related genes, but few studies have reported the correlation between CNVs in morphologically normal tissues adjacent to cancer and cancer progression. In this study, we evaluated cancer cell migration and invasion according to the genetic differences between cancer tissues and their surrounding normal tissues. To study the field cancerization effect, we screened 89 systemic metastasis-related CNVs from morphologically normal tissues adjacent to colon cancers. Among these CNVs, LIM and senescent cell antigen-like domain 2 (PINCH-2) showed copy number amplification and upregulation of mRNA in the nonrelapsed group compared to the systemic relapse group. PINCH-2 expression in colon cancer cells was lower than that in normal epithelial colon cells at both the protein and mRNA levels. Suppression of PINCH-2 resulted in decreased formation of the PINCH-2-IPP (PINCH-2, integrin-linked kinase and α-parvin) complex and reciprocally increased formation of the PINCH-1-IPP complex. Although PINCH-2 expression of survival pathway-related proteins (Akt and phospho-Akt) did not change upon suppression of PINCH-2 expression, cell migration-related proteins [matrix-metalloproteinase (MMP)-9 and -11] were upregulated through autocrine and paracrine activation. Thus, PINCH-2 participates in decreased systemic recurrence by competitively regulating IPP complex formation with PINCH-1, thereby suppressing autocrine and paracrine effects on motility in colon cancer. This genetic change in morphologically normal tissue suggests a field cancerization effect of the tumor microenvironment in cancer progression.
Collapse
Affiliation(s)
- Chan Hee Park
- National Biochip Research Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea; Cancer Metastasis Research Center, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea; Yonsei Cancer Research Institute, Yonsei University College of Medicine, Yonsei University Health System, Seoul, Korea
| | | | | | | | | | | | | | | | | | | |
Collapse
|